Patents by Inventor Kuo-Hsiang Chuang

Kuo-Hsiang Chuang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190022245
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Application
    Filed: August 24, 2018
    Publication date: January 24, 2019
    Applicants: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: STEVEN R ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, Kuo-Hsiang Chuang
  • Publication number: 20190018005
    Abstract: The invention provides a tandemly repeated protein comprising at least two repeats of an amino acid sequence of an antibody binding protein or a fragment thereof and a cell having the repeats expressed on the membrane thereof, which can be used in immunoassay to improve detection sensitivity and detection limit.
    Type: Application
    Filed: July 13, 2017
    Publication date: January 17, 2019
    Inventors: KUO-HSIANG CHUANG, YI-JOU CHEN, MICHAEL CHEN
  • Publication number: 20180146649
    Abstract: The invention relates to a novel non-obese diabetic (NOD) mouse and its application. Particularly, the invention relates to a NOD mouse specifically expressing anti-polyethylene glycol membrane antibody reporter (anti-PEG reporter) in the NOD mouse.
    Type: Application
    Filed: November 29, 2016
    Publication date: May 31, 2018
    Inventor: Kuo-Hsiang CHUANG
  • Publication number: 20170056523
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Application
    Filed: March 2, 2015
    Publication date: March 2, 2017
    Applicants: ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: STEVEN R ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, Kuo-Hsiang Chuang
  • Patent number: 9329180
    Abstract: The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: May 3, 2016
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Tian-Lu Cheng, Steven R. Roffler, Kuo-Hsiang Chuang, Ssu-Jung Lu
  • Patent number: 9315815
    Abstract: The invention provides a method of high-throughput sorting of high expression protein-producing cell, which utilizes linking a protein and a transmembrane domain with a self-processing cleavage site and regulating the secretion of the protein or expression of protein on the cell membrane by adding self-processing cleavage enzyme inhibitor. Then, the high expression cell line can be high-throughput sorted by a detection technique. The invention also provides a recombinant nucleotide sequence and a vector used in the method and a cell sorted by the method.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: April 19, 2016
    Assignee: Taipei Medical University
    Inventors: Kuo-Hsiang Chuang, Tian-Lu Cheng, I-Shiuan Chiang, Yuan-Chin Hsieh
  • Publication number: 20150118693
    Abstract: The invention provides a method of high-throughput sorting of high expression protein-producing cell, which utilizes linking a protein and a transmembrane domain with a self-processing cleavage site and regulating the secretion of the protein or expression of protein on the cell membrane by adding self-processing cleavage enzyme inhibitor. Then, the high expression cell line can be high-throughput sorted by a detection technique. The invention also provides a recombinant nucleotide sequence and a vector used in the method and a cell sorted by the method.
    Type: Application
    Filed: April 28, 2014
    Publication date: April 30, 2015
    Applicant: Taipei Medical University
    Inventors: KUO-HSIANG CHUANG, TIAN-LU CHENG, I-SHIUAN CHIANG, YUAN-CHIN HSIEH
  • Publication number: 20140038208
    Abstract: The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 6, 2014
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: TIAN-LU CHENG, STEVEN R. ROFFLER, KUO-HSIANG CHUANG, SSU-JUNG LU
  • Patent number: 8507207
    Abstract: The invention provides a recombinant nucleotide sequence, including the sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, wherein the recombinant nucleotide sequence encodes an anti-polyethylene glycol recombinant single chain membrane antibody.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: August 13, 2013
    Assignee: Kaohsiung Medical University
    Inventors: Tian-Lu Cheng, Steve R. Roffler, Kuo-Hsiang Chuang
  • Publication number: 20120015380
    Abstract: In this invention, anti-PEG antibodies or anti-methoxyl-PEG (anti-CH3O-PEG) antibodies were expressed on cell surface which can collocate with a biotinylated anti-PEG antibody (AGP4-Biotin) or biotinylated PEG (PEG-Biotin) to develop a cell-based sandwich ELISA or a cell-based competition ELISA, respectively. Both of these two methods could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
    Type: Application
    Filed: February 22, 2011
    Publication date: January 19, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Tian-Lu Cheng, Steven R. Roffler, Kuo-Hsiang Chuang, Ssu-Jung Lu
  • Publication number: 20110064651
    Abstract: The invention provides a recombinant nucleotide sequence, including the sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, wherein the recombinant nucleotide sequence encodes an anti-polyethylene glycol recombinant single chain membrane antibody.
    Type: Application
    Filed: April 26, 2010
    Publication date: March 17, 2011
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Tian-Lu Cheng, Steve R. Roffler, Kuo-Hsiang Chuang